Recent Updates
Recently added Catalysts

nab paclitaxel

Phase 3

Pancreas Adenocarcinoma | Small molecule | Oncology |NovoCure Limited|Last Updated: Jan 21, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment571
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03377491Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)PHASE3 COMPLETED 571 — — May 10, 2018Oct 16, 2024Jan 21, 2026199 United States, Australia +18
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Overall Survival of Subjects Treated With TTFields Concomitant With Gemcitabine and Nab-paclitaxel vs Chemotherapy Alone
From randomization until death from any cause or last known alive.

Overall survival of subjects treated with TTFields concomitant with gemcitabine and nab-paclitaxel in the first line treatment of unresectable, locally advanced pancreatic cancer subjects, compared to overall survival of subjects treated with chemotherapy alone, measured as the period between the time of randomization and the time of death.

Secondary Endpoints
Progression-free Survival of Subjects Treated With TTFields Concomitant With Gemcitabine and Nab-paclitaxel vs Chemotherapy Alone
From randomization until radiologic disease progression per RECIST v1.1 or death, whichever occurs first.
Local Progression-free Survival of Subjects Treated With TTFields Concomitant With Gemcitabine and Nab-paclitaxel vs Chemotherapy Alone
From randomization until local disease progression per RECIST v1.1 (in the absence of distant metastasis) or death, whichever occurs first.
Objective Response Rate of Subjects Treated With TTFields Concomitant With Gemcitabine and Nab-paclitaxel vs Chemotherapy Alone
From randomization until radiologic disease progression per RECIST v1.1 or end of tumor assessment follow-up.
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
NovoTTF-200TEXPERIMENTALPatients receive TTFields using the NovoTTF-200T System together with gemcitabine and nab-Paclitaxel
Best Standard of CareACTIVE_COMPARATORPatients receive best standard of care with gemcitabine and nab-Paclitaxel
Interventions
NameTypeDescription
NovoTTF-200TDEVICEPatients receive continuous TTFields treatment using the NovoTTF-200T device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
GemcitabineDRUGGemcitabine 1000 mg/m\^2 over 30 minute infusion will be administered immediately after nab-paclitaxel on Days 1, 8 and 15 of each 28-day cycle.
nab paclitaxelDRUGnab-paclitaxel 125 mg/m\^2 administered as an intravenous infusion over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites199

Inclusion Criteria: 1. 18 years of age and older 2. Life expectancy of ≥ 3 months 3. Histological/cytological diagnosis of de novo adenocarcinoma of the pancreas 4. Unresectable, locally advanced stage disease according to the following criteria: * Head/uncinate process: 1. Solid tumor co...

Countries:United StatesAustraliaAustriaBelgiumBrazilCanadaChinaCroatiaCzechiaFranceGermanyHong KongHungaryIsraelItalyMexicoPolandSouth KoreaSpainSwitzerland
Unlock Eligibility Criteria